- Home
- SKE vs ANIP Comparison
SKE vs ANIP Comparison
Compare SKE & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKE
- ANIP
- Stock Information
- Founded
- SKE 1979
- ANIP 2001
- Country
- SKE Canada
- ANIP United States
- Employees
- SKE N/A
- ANIP N/A
- Industry
- SKE Precious Metals
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- SKE Basic Materials
- ANIP Health Care
- Exchange
- SKE Nasdaq
- ANIP Nasdaq
- Market Cap
- SKE 1.8B
- ANIP 1.4B
- IPO Year
- SKE N/A
- ANIP N/A
- Fundamental
- Price
- SKE $15.45
- ANIP $67.48
- Analyst Decision
- SKE
- ANIP Strong Buy
- Analyst Count
- SKE 0
- ANIP 9
- Target Price
- SKE N/A
- ANIP $80.56
- AVG Volume (30 Days)
- SKE 410.8K
- ANIP 288.7K
- Earning Date
- SKE 08-07-2025
- ANIP 08-05-2025
- Dividend Yield
- SKE N/A
- ANIP N/A
- EPS Growth
- SKE N/A
- ANIP N/A
- EPS
- SKE N/A
- ANIP N/A
- Revenue
- SKE N/A
- ANIP $674,068,000.00
- Revenue This Year
- SKE N/A
- ANIP $30.84
- Revenue Next Year
- SKE N/A
- ANIP $7.39
- P/E Ratio
- SKE N/A
- ANIP N/A
- Revenue Growth
- SKE N/A
- ANIP 30.27
- 52 Week Low
- SKE $5.63
- ANIP $52.50
- 52 Week High
- SKE $17.25
- ANIP $77.00
- Technical
- Relative Strength Index (RSI)
- SKE 47.58
- ANIP 58.60
- Support Level
- SKE $15.89
- ANIP $64.27
- Resistance Level
- SKE $16.85
- ANIP $68.20
- Average True Range (ATR)
- SKE 0.62
- ANIP 2.04
- MACD
- SKE -0.14
- ANIP 0.09
- Stochastic Oscillator
- SKE 30.90
- ANIP 77.60
About SKE Skeena Resources Limited
Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.